RA

Reinhard Ambros

Chairman Of The Board at ImmunOs Therapeutics AG

Basel, Basel

Angel

Invests in

Stages:

Seed
Pre-seed

  • Min Investment:

    $5,000.00

  • Max Investment:

    $50,000.00

  • Target Investment:

    $25,000.00

Skills

Pharmaceutical Industry
Biotechnology
Lifesciences
Technology Transfer
Clinical Development
Drug Development
Drug Discovery
Oncology
Commercialization
Medical Devices
Corporate Development
Venture Capital
R&D
Biopharmaceuticals
Mergers
Strategy

Education

Lists including Reinhard

AM
AT
AS
AR

All Seed Investors

19695 people

AT
AE
AE
AL

All Pre-Seed Investors

7974 people

Investments

ImmunOs Therapeutics

Series A

Total Funding: $88M

Aileron Therapeutics

Series A

Total Funding: $140M

FORMA Therapeutics

Series A

Total Funding: $33M

Work Experience

G
Genedata

2006

  • Board Of Directors

    2006

V
Viridos

2018

  • Board Of Directors

    2018

AT
Aileron Therapeutics

2013

  • Board Of Directors

    2013

    Board member Aileron Therapeutics

T
TruDataRx

2019

  • Board Of Directors

    2019

IT
ImmunOs Therapeutics AG

2019

  • Chairman of the Board of Directors

    2019

A
ARTIDIS

2018 - 2024

  • Board Of Directors

    2018 - 2024

Tt
TOLREMO therapeutics AG

2019 - 2023

  • Chairman of the Board of Directors

    2019 - 2023

VA
Versameb AG

2019 - 2022

  • Chairman Of The Board

    2019 - 2022

N
Novartis

2005 - 2018

  • Head Novartis Venture Funds

    2005 - 2018

    Built the Novartis Venture Fund and management team to one of the largest and most active corporate venture fund in life sciences with about 1 bn$ under management.

N
Novartis

1999 - 2004

  • Head Novartis Group Strategy

    2001 - 2004

    Develop the Novartis group strategy

  • Head BD&L for Cardiovascular and Metabolism

    1999 - 2001

    Leading in/out licensing projects